Search - tctmd.com

Displaying 1 - 13 of 13

Sort: Relevancy | Date

News Features

Major TAVI Studies Have ‘Methodological Issues,’ INTEGRITTY Group Contends

Michael O'Riordan

January 06, 2023

News Features

Novel Targets, Gene Edits, and Vaccines: Is a ‘Golden Era’ Dawning for ASCVD?

Michael O'Riordan

August 15, 2022

News Features TVT 2022

Minorities, Poorer Patients Missing Out on Structural Heart Care

Michael O'Riordan

June 15, 2022

News Features

Pricey Inclisiran Is Rolling Out: a ‘Buy-and-Bill’ Model May Smooth Its Path

Michael O'Riordan

January 17, 2022

News Features

FFR’s Future: Negative Trials Spur Debate Over Technology’s Role

Michael O'Riordan

December 23, 2021

News Features

Four Pillars, Fast? Rapid Sequencing of HF Drugs Faces an Uphill Battle

Shelley Wood

October 08, 2021

News Features

Roughly 80% of ESC Guideline Writers Have Financial COIs

Michael O'Riordan

April 01, 2021

News Features

Funding the Future: How Industry Support for CV Trials Could Evolve

Michael O'Riordan

December 17, 2020

News Features

Too Easy to Misconstrue: Is It Time to Ditch Periprocedural MI?

Michael O'Riordan

December 02, 2020

News Features

EXCEL Investigators Respond to Data Suppression Claims as Debate Erupts Online

Michael O'Riordan

December 12, 2019

News Features

Top News in Prevention: 2018

Michael O'Riordan

December 28, 2018

News Features

Mercury Rising: As Doctors’ Groups Face Off Over BP Guidelines, Will Patients Fall Through the Cracks?

L.A. McKeown

February 26, 2018

News Features

Trajectory Unknown: How ORBITA Lands in Clinical Practice Still Up for Debate

Michael O'Riordan

November 27, 2017

Advertisement

Major TAVI Studies Have ‘Methodological Issues,’ INTEGRITTY Group Contends

Novel Targets, Gene Edits, and Vaccines: Is a ‘Golden Era’ Dawning for ASCVD?

Minorities, Poorer Patients Missing Out on Structural Heart Care

Pricey Inclisiran Is Rolling Out: a ‘Buy-and-Bill’ Model May Smooth Its Path

FFR’s Future: Negative Trials Spur Debate Over Technology’s Role

Four Pillars, Fast? Rapid Sequencing of HF Drugs Faces an Uphill Battle

Roughly 80% of ESC Guideline Writers Have Financial COIs

Funding the Future: How Industry Support for CV Trials Could Evolve

Too Easy to Misconstrue: Is It Time to Ditch Periprocedural MI?

EXCEL Investigators Respond to Data Suppression Claims as Debate Erupts Online

Top News in Prevention: 2018

Mercury Rising: As Doctors’ Groups Face Off Over BP Guidelines, Will Patients Fall Through the Cracks?

Trajectory Unknown: How ORBITA Lands in Clinical Practice Still Up for Debate

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content